NYSE:SYKStryker Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Stryker Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $176.51 +10.72 (+6.47 %) (As of 04/8/2020 03:14 PM ET) Add Compare Share Today's Range$166.51Now: $176.51▼$177.6150-Day Range$126.50MA: $176.34▼$225.1052-Week Range$124.54Now: $176.51▼$226.30Volume1.45 million shsAverage Volume2.29 million shsMarket Capitalization$66.16 billionP/E Ratio32.21Dividend Yield1.39%Beta0.84 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 80 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingStryker has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 15 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $211.10, Stryker has a potential upside of 19.8% from its current price of $176.19.Amount of Analyst CoverageStryker has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesStryker has received 779 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStryker has received 755 “underperform” votes. (Add your “underperform” vote.)Community SentimentStryker has received 50.78% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote “Outperform” if you believe SYK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 4.2 Dividend Strength Dividend LeadershipStryker is a leading dividend payer. It pays a dividend yield of 1.39%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthStryker has been increasing its dividend for 9 years.Dividend CoverageThe dividend payout ratio of Stryker is 27.85 %. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Stryker will have a dividend payout ratio of 24.01 % next year. This indicates that Stryker will be able to sustain or increase its dividend. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stryker insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,750.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Stryker is held by insiders.Percentage Held by Institutions73.10% of the stock of Stryker is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Stryker are expected to grow by 11.01% in the coming year, from $8.63 to $9.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stryker is 32.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.21.Price to Earnings Ratio vs. SectorThe P/E ratio of Stryker is 32.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.80.Price to Earnings Growth RatioStryker has a PEG Ratio of 2.10. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioStryker has a P/B Ratio of 5.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 4.2Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.92 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:SYK Previous Symbol CUSIP86366710 CIK310764 Webhttp://www.strykercorp.com/ Phone269-389-2600Debt Debt-to-Equity Ratio0.80 Current Ratio2.58 Quick Ratio1.84Price-To-Earnings Trailing P/E Ratio32.21 Forward P/E Ratio20.45 P/E Growth2.1 Sales & Book Value Annual Sales$14.88 billion Price / Sales4.45 Cash Flow$12.48 per share Price / Cash Flow14.14 Book Value$34.23 per share Price / Book5.16Profitability EPS (Most Recent Fiscal Year)$8.26 Net Income$2.08 billion Net Margins13.99% Return on Equity25.75% Return on Assets11.51%Miscellaneous Employees40,000 Outstanding Shares374,828,000Market Cap$66.16 billion Next Earnings Date4/28/2020 (Estimated) OptionableOptionable Receive SYK News and Ratings via Email Sign-up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter. SYK Rates by TradingView Stryker (NYSE:SYK) Frequently Asked Questions How has Stryker's stock been impacted by COVID-19 (Coronavirus)? Stryker's stock was trading at $175.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SYK stock has increased by 0.3% and is now trading at $176.19. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Stryker? 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 1 sell rating, 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stryker. When is Stryker's next earnings date? Stryker is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Stryker. How were Stryker's earnings last quarter? Stryker Co. (NYSE:SYK) issued its quarterly earnings results on Tuesday, January, 28th. The medical technology company reported $2.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.46 by $0.03. The medical technology company earned $4.13 billion during the quarter, compared to the consensus estimate of $4.11 billion. Stryker had a return on equity of 25.75% and a net margin of 13.99%. Stryker's revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company posted $2.18 EPS. View Stryker's earnings history. How often does Stryker pay dividends? What is the dividend yield for Stryker? Stryker declared a quarterly dividend on Friday, February 7th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.575 per share on Thursday, April 30th. This represents a $2.30 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date of this dividend is Monday, March 30th. View Stryker's dividend history. What guidance has Stryker issued on next quarter's earnings? Stryker updated its FY20 earnings guidance on Tuesday, January, 28th. The company provided EPS guidance of $9.00-9.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.04. What price target have analysts set for SYK? 22 analysts have issued 1 year price objectives for Stryker's shares. Their forecasts range from $145.00 to $248.00. On average, they expect Stryker's share price to reach $211.10 in the next twelve months. This suggests a possible upside of 19.8% from the stock's current price. View analysts' price targets for Stryker. Has Stryker been receiving favorable news coverage? Media coverage about SYK stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Stryker earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the medical technology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutStryker. Are investors shorting Stryker? Stryker saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 5,538,700 shares, an increase of 43.9% from the February 27th total of 3,850,000 shares. Based on an average trading volume of 1,640,000 shares, the days-to-cover ratio is currently 3.4 days. Approximately 1.6% of the company's stock are short sold. View Stryker's Current Options Chain. Who are some of Stryker's key competitors? Some companies that are related to Stryker include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD), Masimo (MASI) and Varian Medical Systems (VAR). What other stocks do shareholders of Stryker own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stryker investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Home Depot (HD), Medtronic (MDT), Visa (V), AbbVie (ABBV), NVIDIA (NVDA), Boeing (BA), Bank of America (BAC) and Abbott Laboratories (ABT). Who are Stryker's key executives? Stryker's management team includes the following people: Mr. Kevin A. Lobo, Chairman & CEO (Age 54)Mr. Timothy J. Scannell, Pres & COO (Age 54)Mr. Glenn S. Boehnlein, VP & CFO (Age 57)Mr. Michael D. Hutchinson, VP & Chief Legal Officer (Age 48)Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 57) What is Stryker's stock symbol? Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK." Who are Stryker's major shareholders? Stryker's stock is owned by many different retail and institutional investors. Top institutional investors include LGT Capital Partners LTD. (0.10%), CWS Financial Advisors LLC (0.08%), Bath Savings Trust Co (0.02%), State of Alaska Department of Revenue (0.02%), McGuire Investment Group LLC (0.02%) and First Financial Bank Trust Division (0.01%). Company insiders that own Stryker stock include Allan C Golston, Bijoy Sagar, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Roch Doliveux, Srikant M Datar, Timothy J Scannell and Yin C Becker. View institutional ownership trends for Stryker. Which major investors are selling Stryker stock? SYK stock was sold by a variety of institutional investors in the last quarter, including CLARET ASSET MANAGEMENT Corp, CWS Financial Advisors LLC, Cypress Capital Group, Hotaling Investment Management LLC, Indiana Trust & Investment Management CO, Mountain Pacific Investment Advisers Inc. ID, West Oak Capital LLC, and Woodstock Corp. Company insiders that have sold Stryker company stock in the last year include Allan C Golston, Bijoy Sagar, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Louise Francesconi, M Kathryn Fink, Srikant M Datar, and Timothy J Scannell. View insider buying and selling activity for Stryker. Which major investors are buying Stryker stock? SYK stock was purchased by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD., State of Alaska Department of Revenue, Lake Street Financial LLC, American National Bank, IBM Retirement Fund, Cullinan Associates Inc., Bath Savings Trust Co, and First Financial Bank Trust Division. View insider buying and selling activity for Stryker. How do I buy shares of Stryker? Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Stryker's stock price today? One share of SYK stock can currently be purchased for approximately $176.19. How big of a company is Stryker? Stryker has a market capitalization of $66.04 billion and generates $14.88 billion in revenue each year. The medical technology company earns $2.08 billion in net income (profit) each year or $8.26 on an earnings per share basis. Stryker employs 40,000 workers across the globe. View additional information about Stryker. What is Stryker's official website? The official website for Stryker is http://www.strykercorp.com/. How can I contact Stryker? Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Why are percentage gainers important?
